Skip to main content

180 Life Sciences Corp.

For the period ended Jul 24, 2025. Filed Jul 7, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jul 24, 2025 · Filed Jul 7, 2025

FRMM$3.040.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

**UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

Filed by the Registrant☒
Filed by party other than the registrant☐

Check the appropriate box:

☐Preliminary Proxy Statement
☐Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))
☒Definitive Proxy Statement
☐Definitive additional materials
☐Soliciting material under Rule 14a-12

**180 LIFE SCIENCES CORP.

**(Name of Registrant as Specified in Charter)

Payment of Filing Fee (Check all boxes that apply):

☒No fee required
☐Fee paid previously with preliminary materials
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

3000 El Camino Rd., Bldg. 4, Suite 200

Palo Alto, California 94306

July 7, 2025

To Our Stockholders:

The Board of Directors (“Board”) and officers of 180 Life Sciences Corp., a Delaware corporation (the “Company”), join us in extending to you a cordial invitation to attend the 2025 annual meeting of our stockholders, which we refer to as the annual meeting or the Meeting, to be held (subject to postponement(s) or adjournment(s) thereof):

Date:Thursday, July 24, 2025
Time:9:00 a.m. Pacific Time
Virtual Meeting Site:https://agm.issuerdirect.com/ATNF-2025

You will not be able to attend the annual meeting physically. The annual meeting will be held via an audio teleconference. Stockholders may attend, vote and submit questions during the annual meeting via the Internet by logging in athttps://agm.issuerdirect.com/ATNF-2025, with your Control ID and Request ID, and thereafter following the instructions to join the virtual meeting. In addition to voting by submitting your proxy prior to the annual meeting and/or voting online as discussed herein, you also will be able to vote your shares electronically during the annual meeting with your Request ID. Details regarding the business to be conducted are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement.

The Notice of Annual Meeting and Proxy Statement, is also available athttps://www.iproxydirect.com/ATNF. This website also includes copies of our Annual Report on Form 10-K for the year ended December 31, 2024, which we refer to as the annual report. Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650) 507-0669.

In connection with the annual meeting, you will be asked to consider and vote on certain proposals, which are more fully described in the accompanying proxy statement. Whether or not you plan to attend the annual meeting, we urge you to read the proxy statement (and any documents incorporated into the proxy statement by reference) and consider such information carefully before voting. The attached Notice of Annual Meeting and the Proxy Statement describe the business to be considered and acted upon by the stockholders at the annual meeting. Please review these materials and vote your shares.

Your vote is very important. Even if you plan to attend the annual meeting, if you are a holder of record of voting stock please submit your proxy by mail, fax, Internet or telephone as soon as possible to make sure that your shares are represented at the annual meeting. If you hold your shares of Company stock in “street name” through a bank, broker, or other nominee, you must vote in accordance with the voting instructions provided to you by such bank, broker, or other nominee, which include instructions for voting by Internet or telephone.

Our Board of Directors encourages your participation in 180 Life Sciences Corp.’s electoral process and, to that end, solicits your proxy with respect to the matters described in the Notice of Meeting and the proxy statement.

We look forward to seeing you on July 24, 2025. Your vote and participation in our governance is very important to us.

Sincerely,

/s/ Blair Jordan

Blair Jordan

Chief Executive Officer and Director

Our proxy statement and Annual Report on Form 10-K for the year ended December 31, 2024 are available at the following cookies-free website that can be accessed anonymously:https://agm.issuerdirect.com/ATNF-2025. Stockholders may also vote prior to the meeting atwww.iproxydirect.com/ATNF.

**180 LIFE SCIENCES CORP.

**3000 El Camino Rd., Bldg. 4, Suite 200

Palo Alto, California 94306

**NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JULY 24, 2025

To the Stockholders of 180 Life Sciences Corp.:

We are pleased to provide you notice of, and to invite you to attend, the 2025 annual meeting of the stockholders of 180 Life Sciences Corp., a Delaware corporation (“180 Life”, the “Company”, “we” and “us”), which will be held on Thursday, July 24, 2025, at 9:00 a.m., Pacific Time (subject to postponement(s) or adjournment(s) thereof), which we refer to as the annual meeting, or the “Meeting”. The meeting will be held virtually via live audio webcast athttps://agm.issuerdirect.com/ATNF-2025. See also “Instructions For The Virtual Annual Meeting”, beginning on page 1. The annual meeting is being held for the following purposes:

1.To elect two Class I directors to the Board of Directors (the “Board”) each to serve a term of two years and until their respective successors have been elected and qualified, or until such director’s resignation or removal. The Board has nominated for re-election the following incumbent Class I directors: Lawrence Steinman, M.D. and Stephen H. Shoemaker.
2.To approve the adoption of the Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan. The Board of Directors recommends that you approve and ratify the Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan.
3.To approve the adoption of the 180 Life Sciences Corp. 2025 Option Incentive Plan. The Board of Directors recommends that you approve and ratify the 180 Life Sciences Corp. 2025 Option Incentive Plan.
4.To approve an advisory resolution on Named Executive Officer compensation. The Board of Directors recommends that you approve and ratify executive compensation.
5.To approve an Amendment to the Company’s Second Amended and Restated Certificate of Incorporation to approve a reverse stock split of the Company’s outstanding common stock. The Board of Directors recommends that you grant discretionary authority to the Company’s Board of Directors to (A) approve an amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of our common stock, par value $0.0001 per share, by a ratio of between one-for-four to one-for-forty, inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to July 24, 2026, and (B) determine whether to arrange for the disposition of fractional interests by shareholder entitled thereto, to pay in cash the fair value of fractions of a share of common stock as of the time when those entitled to receive such fractions are determined, or to entitle shareholder to receive from the Corporation’s transfer agent, in lieu of any fractional share, the number of shares of common stock rounded up to the next whole number (the “Reverse Split Proposal”).
6.To approve an Amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the Company’s authorized number of shares of common stock from one hundred million (100,000,000) shares to one billion (1,000,000,000) shares. The Board of Directors recommends that you approve an Amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the Company’s authorized number of shares of common stock from one hundred million (100,000,000) shares to one billion (1,000,000,000) shares (the “Authorized Share Increase Proposal”).
7.To ratify the appointment of M&K CPAs, PLLC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2025. The Board of Directors recommends that you approve and ratify the appointment of M&K CPAs, PLLC as the Company’s independent auditors for the fiscal year ending December 31, 2025.
8.To approve the adjournment of the Annual Meeting, if necessary. The Board of Directors recommends that you approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Reverse Split Proposal and/or Authorized Share Increase Proposal.
9.To transact such other business as may properly come before the annual meeting.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR ALL” FOR PROPOSAL ONE, AND “FOR” PROPOSALS TWO THROUGH EIGHT.

Any action may be taken on any one of the foregoing proposals at the Meeting on the date specified above or on any date or dates to which the Meeting may be postponed or adjourned. We do not expect to transact any other business at the annual meeting. Our Board of Directors has fixed the close of business on June 30, 2025, as the record date for determining those stockholders entitled to vote at the annual meeting and any adjournment or postponement thereof. Accordingly, only common and preferred stock stockholders of record at the close of business on that date are entitled to notice of, and to vote at, the annual meeting.

We cordially invite you to attend the annual meeting. However, to ensure your representation at the annual meeting, please authorize the individuals named on your proxy card to vote your shares by calling the toll-free telephone number, faxing your proxy card or by using the Internet as described in the instructions included with your proxy card or voting instruction card. Alternatively, if you received a paper copy of the proxy card by mail, please complete, date, sign and promptly return the proxy card. This will not prevent you from voting at the meeting, but will help to secure a quorum and avoid added solicitation costs. If your shares are held in “street name” by your broker or other nominee, only that holder can vote your shares and the vote cannot be cast unless you provide instructions to your broker. You should follow the directions provided by your broker regarding how to instruct your broker to vote your shares. Your proxy may be revoked at any time before it is voted. Please review the proxy statement accompanying this notice for more complete information regarding the matters to be voted on at the meeting.

The enclosed proxy statement is first being mailed to stockholders on or about July 7, 2025, is also available athttps://www.iproxydirect.com/ATNF. This website also includes our Annual Report on Form 10-K for the year ended December 31, 2024, which we refer to as the 2024 Annual Report. Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650) 507-0669.

Even if you plan to attend the annual meeting, we request that you submit a proxy by following the instructions on your proxy card as soon as possible and thus ensure that your shares will be represented at the annual meeting if you are unable to attend.

If you have any questions or require any assistance with voting your shares, please contact our proxy agent, Issuer Direct Corporation at (919) 481-4000, or 1-866-752-VOTE (8683).

By Order of the Board of Directors:

/s/ Blair Jordan

Blair Jordan

Chief Executive Officer and Director

Palo Alto, California

July 7, 2025

IMPORTANT: WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, WE ASK YOU TO VOTE BY TELEPHONE, MAIL, FAX OR ON THE INTERNET USING THE INSTRUCTIONS ON THE PROXY CARD.

TABLE OF CONTENTS

General Information1
Information Contained in this Proxy Statement1
Instructions For The Virtual Annual Meeting1
Questions During the Annual Meeting1
Technical Difficulties or Trouble Accessing the Virtual Meeting Website2
Record Date and Shares Entitled to Vote2
Voting Process2
Providing and Revoking Proxies3
Meeting Time and Location: Virtual Annual Meeting3
Conduct at the Meeting3
Voting Requirements for Each of the Proposals4
Quorum5
Board of Directors Voting Recommendations5
Mailing Costs and Solicitation of Proxies6
Inspector of Voting6
Stockholders Entitled to Vote at the Meeting6
Voting Instructions6
Confidential Voting6
Stockholder of Record and Shares Held in Brokerage Accounts7
Multiple Stockholders Sharing the Same Address7
Voting Results7
Company Mailing Address7
Other Matters7
Background of the Company8
Prior Reverse Stock Splits8
Definitions8
Forward-Looking Statements and Website Links9
Incorporation by Reference9
References to Additional Information9
Voting Rights and Principal Stockholders10
Security Ownership of Management and Certain Beneficial Owners and Management10
Change of Control12
Corporate Governance13
Board Leadership Structure13
Risk Oversight13
Family Relationships14
Other Directorships14
Involvement in Certain Legal Proceedings14
Board of Directors Meetings15
Board Committee Membership15
Audit Committee15
Compensation Committee16
Compensation Committee Interlocks and Insider Participation17
Nominating and Governance Committee17
Strategy and Alternatives, Risk, Safety and Regulatory Committee18
Website Availability of Documents18
Stockholder Communications with the Board of Directors18
Lead Independent Director19

i

Executive Sessions of the Board of Directors19
Code of Ethics19
Policy on Equity Ownership19
Rule 10b5-1 Trading Plans19
Compensation Recovery and Clawback Policies19
Insider Trading/Anti-Hedging Policies20
Policy on Timing of Award Grants21
Director Independence21
Audit Committee Report22
Information About Our Executive Officers and Directors23
Executive Officers23
Classified Board of Directors23
Director Nominees24
Continuing Directors26
Director Qualifications27
Executive and Director Compensation27
Summary Executive Compensation Table27
Bonuses29
Current Compensation Agreements29
Jordan Consulting Agreement29
EVL Consulting Agreement32
Prior Employment Agreements33
James N. Woody Amended and Restated Employment Agreement (terminated); and Separation Agreement33
Dr. Rothbard’s Employment Agreement (terminated); and Separation Agreement35
Ozan Pamir Katexco Employment Agreement (Terminated)35
Ozan Pamir Company Employment Agreement (Terminated)36
Quan Anh Vu Executive Employment Agreement (terminated); and Separation Agreement36
Description of Material Consulting Agreements37
Service Agreement with Prof. Sir Marc Feldmann (former Co-Executive Chairman)(Terminated)37
Consultancy Agreement and Consulting Agreement with Prof. Lawrence Steinman39
Prof. Jagdeep Nanchahal Consulting Agreement40
Payment of Back Pay; 2021 Bonuses and Increases in Salaries42
2024 Accruals42
2022, 2023 and 2024 Bonuses42
Pay Versus Performance43
Relationship Between “Compensation Actually Paid” and Performance46
Compensation Actually Paid and Net Loss46
Compensation Actually Paid and Cumulative TSR46
Outstanding Equity Awards at Fiscal Year End47
Potential Payments Upon Termination47
Director Compensation48
Board of Director Fees49
Release Agreement49
Accelerated Vesting of February 2025 RSU Awards50
June 2025 Option Grants50
June 2025 Restricted Stock Awards50
Equity Compensation Plan Information51
2020 Omnibus Incentive Plan51
2022 Omnibus Incentive Plan51
Certain Relationships and Related Party Transactions52
Related Party Agreements52
Service Agreement with Prof. Sir Marc Feldmann52
Prof. Jagdeep Nanchahal Consulting Agreement53
Prof. Lawrence Steinman Consultancy Agreement and Consulting Agreement53

ii

Jordan Consulting Agreement53
EVL Consulting Agreement53
Voting Agreements53
Conversion of Series B Convertible Preferred Stock54
Elray and Luxor Settlement Agreement54
General and Administrative - Related Parties55
Accounts Payable - Related Parties55
Research and Development Expenses – Related Parties55
Release Agreement with Jay Goodman55
Accelerated RSU Vesting, RSU Grants and Option Grants55
Related Party Litigation56
Action Against Former Executive of KBL56
Action Against the Company by Dr. Krauss56
Action Against Tyche Capital LLC57
Action Against Ronald Bauer & Samantha Bauer58
Declaratory Relief Action Against the Company by AmTrust International58
Indemnification Agreements60
Related Party Transaction Policy60
Delinquent Section 16(a) Reports60
Proposal 1 Election of Directors61
General61
General Director Qualifications61
What Vote Is Required To Elect the Director Nominees61
Board Recommendation61
Proposal 2 Adoption of the Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan62
General62
Background and Purpose of the Amended Plan62
Current Overview of Outstanding Equity Information63
Summary of the Material Terms of the Amended Plan63
Federal Income Tax Consequences68
Vote Required70
Board Recommendation70
PROPOSAL 3 APPROVAL OF THE 180 LIFE SCIENCES CORP. 2025 OPTION INCENTIVE PLAN71
General71
2025 Plan Option Grants71
Background and Purpose of the 2025 Plan72
Summary of the Material Terms of the 2025 Plan72
Federal Income Tax Consequences75
Effect of Approval77
Vote Required77
Board Recommendation77
Proposal 4 Approval of an Advisory Resolution on Named Executive Officer Compensation78
General78
Vote Required78
Board Recommendation78
Proposal 5 Amendment to Second Amended and Restated Certificate of Incorporation, as Amended, to Effect a Reverse Stock Split79
General79
Purpose79
Accounting Matters82
Risks of the Proposed Reverse Stock Split82
Principal Effects of the Reverse Stock Split83
Fractional Shares87
Determination of the Reverse Stock Split Ratio87
Potential Consequences if the Reverse Split Proposal is Not Approved88
Effective Date and Time of the Reverse Stock Split88
No Dissenters’ Rights88
Certain United States Federal Income Tax Consequences89
Exchange of Stock Certificates91
Book-Entry Shares92
Interests of Directors and Executive Officers92
Vote Required92
Board Recommendation92

iii

Proposal 6 Approval of an Amendment to Our Second Amended and Restated Certificate of Incorporation to Increase the Company’s Authorized Number of Shares of Common Stock From One Hundred Million (100,000,000) to One Billion (1,000,000,000)93
General93
Reasons for the Amendment93
Summary Table of Potential Effects of Authorized Share Increase95
No Dissenters’ Rights96
Effective Time and Implementation of the Authorized Shares Increase Amendment96
Vote Required96
Board Recommendation96
Proposal 7 Ratification of Appointment of Auditors96
Change in Independent Registered Public Accounting Firm96
Principal Accounting Fees and Services97
Audit Committee Policy for Pre-approval of Independent Registered Public Accounting Firm Services98
Pre-Approval Policies98
Vote Required98
Board Recommendation98
Proposal 8 Adjournment of the Annual Meeting to Solicit Additional Proxies99
Overview99
Vote Required99
Board Recommendation99
Other Matters100
Proposals for 2026 Annual Meeting of Stockholders and 2026 Proxy Materials100
Proxy Statement Proposals100
Other Proposals and Nominations100
Additional Filings101
Other Matters to be Presented at the Annual Meeting101
Interest of Certain Persons in or Opposition to Matters to Be Acted Upon:101
Incorporation by Reference102
Company Contact Information102

iv

Appendixes:

Appendix A—Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan
Appendix B—Fourth Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan
Appendix C—180 Life Sciences Corp. 2025 Option Incentive Plan
Appendix D—Form of Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of 180 Life Sciences Corp. in Connection with the Reverse Stock Split Proposal
Appendix E—Form of Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of 180 Life Sciences Corp. in Connection with the Authorized Share Increase Proposal

v

**PROXY STATEMENT

FOR 2025 ANNUAL MEETING OF STOCKHOLDERS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.